Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
Date:3/10/2010

itability and positive cash flow have allowed the Company to retain the majority of the proceeds for potential new acquisitions.

International Markets

In 2009, the Company announced that it entered into exclusive agreements with Phebra Pty Ltd. for commercialization of Caldolor in Australia and New Zealand, and with DB Pharm Korea for registration and commercialization of the product in South Korea. Phebra and DB Pharm Korea will be responsible for obtaining regulatory approval for Caldolor in their respective territories, and for handling ongoing regulatory requirements, product marketing, distribution and sales. Cumberland will maintain responsibility for product formulation, development and manufacturing, and will provide finished product for sale. Cumberland will receive upfront and milestone payments as well as a transfer price from the partnering companies, and will also receive royalties on any sales of Caldolor in those territories.

New Intellectual Property Initiative for Caldolor


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
(Date:7/24/2014)... /PRNewswire-iReach/ -- "North America Orthopedic Braces and Supports Market ... North America Orthopedic Braces and Supports market. The report ... (in units) and average price data (in US dollars), ... Supports , Ankle Braces and Supports , ... and Supports. Photo - ...
(Date:7/24/2014)... GLASGOW, Scotland , July 24, 2014 Cancer ... will gain access to state-of-the-art cancer treatment closer to home ... next year. Varian Medical Systems (NYSE: ... and an order was placed in June for four TrueBeam™ ... TrueBeam systems, which offer fast and efficient radiotherapy and radiosurgery ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... 16 Patient enrollment into the GRAVITAS,(Gauging Responsiveness ... has begun, officials from Accumetrics announced today. The,GRAVITAS ... the VerifyNow P2Y12 test,to identify patients that exhibit ... risk for adverse cardiac events, and prove that ...
... New research continues to reinforce the efficacy of RESPeRATE ... by the scientific community, BERLIN and NEW YORK, ... 21, Hall 15.1 -- InterCure Ltd., a medical device,company ... today,announced the findings of new studies and analysis highlighting ...
Cached Medicine Technology:Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial 2Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial 3Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 3Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 4
(Date:7/24/2014)... 25, 2014 Journal of Oral ... by the width of the alveolar ridge—an indication of ... A variety of methods exist, each with their own ... The ridge-split graft is highlighted as a strategy for ... Oral Implantology offers a comparison of two commonly ...
(Date:7/24/2014)... breast tumors, exposure to dim light at night made ... according to data published in Cancer Research , ... The negative effects of dim light exposure on tamoxifen ... during the night. , "Resistance to tamoxifen is a ... said Steven M. Hill, PhD, professor of structural and ...
(Date:7/24/2014)... Triangle Park, NC (PRWEB) July 24, 2014 ... elderly, ethnic minorities, and low-income households are disproportionately ... and public food safety net in the United ... International. , Under Section 743 of the Consolidated ... U.S. Department of Agriculture's Food and Nutrition Service ...
(Date:7/24/2014)... IL (PRWEB) July 24, 2014 In a ... infertility expert and founder of Lotus Blossom Consulting LLC ... Rosato entitled Three Ways to Cut the High Cost ... way to minimize costs is to maximize your chance of ... advice on choosing a clinic. , “I am always ...
(Date:7/24/2014)... Diabetes mellitus (DM) appears to increase the risk for head ... common in people with DM, but the risk of HNC ... head and neck cancer is the sixth most common type ... cases and for an estimated 650,000 new cancer cases and ... Taiwan,s Longitudinal Health Insurance Research Database to examine the risk ...
Breaking Medicine News(10 mins):Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3
... to a study, there is a connection between certain ... a possibility of using probiotics to treat autism.// ... Reading conducted this study. Though the results are very ... did not propose any link between autism and childhood ...
... medical tourism has created new vistas, enabling a panorama ... In the race for being the best in the ... industry’s powerful trident - Pharmaceutical Industry, Doctors and Pharmacists, ... as diseases”, said Karl Marx, and what better time ...
... comfortable with the outcome of drug coated heart stents, once ... of formation of fatal blood clots. The drug-coated stents were ... of bare-metal stents. ,It is estimated that ... the stents, which are designed to ensure the arteries are ...
... Children suffering from Attention Deficit Hyperactivity Disorder (ADHD) cannot ... instructions.// Though mental health professionals and parents are familiar ... still a controversial topic. ,The FDA has ... and Adderall XR should put up warnings about the ...
... the British chairman of the International Obesity Task Force, ... obesity epidemic in poor countries. ,"The trade ... subsidize and distort the market to make fats and ... said at the 10th International Obesity Congress in Sydney, ...
... President A.P.J. Abdul Kalam Monday inaugurated the 150th anniversary ... of the oldest //and most prestigious educational institutions in ... called for moral leadership and greater research. "Good teaching ... research it produces," Kalam told students and academics here. ...
Cached Medicine News:Health News:Probiotics – a probable treatment for Autis 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 3Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 4Health News:Alternative therapies for ADHD 2Health News:Alternative therapies for ADHD 3Health News:President Launches Madras University's 150th Year Celebrations 2
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system....
Measure SpO2 and tcpCO2 with a single sensor....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: